SCHEMBL2365672

SCHEMBL2365672

O=C(O)c1cccc(Sc2ccc(Cl)cn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ENPP2 Q13822 4/20 0.49
PRKAG1 P54619 2/20 0.48
PRKAA2 P54646 2/20 0.48
PRKAB1 Q9Y478 2/20 0.48
BRAF P15056 2/20 0.46
KDR P35968 2/20 0.46
APEX1 P27695 1/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
MAP4K4 O95819 1/20 0.43
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
NR4A2 P43354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13366022 0.83 BRAF (0.61) BRAFKDRMEN1KMT2AALDH1A1
SCHEMBL2365633 0.83 BRAF (0.47) HPGDCYP1A2CYP2C9BRAFKDR
SCHEMBL3172222 0.81 CYP1A2 (0.46) HPGDCYP1A2CYP2C9HSD17B10ENPP2
SCHEMBL1002444 0.79 ALDH1A1 (0.54) HPGDCYP1A2CYP2C9HSD17B10PRKAG1
SCHEMBL7665445 0.77 GRM5 (0.49) HPGDCYP1A2CYP2C9HSD17B10ENPP2
SCHEMBL3378744 0.77 L3MBTL1 (0.53) HPGDCYP1A2CYP2C9MAPTMEN1
SCHEMBL2406839 0.77 CYP1A2 (0.76) HPGDCYP1A2CYP2C9HSD17B10ENPP2
SCHEMBL31383422 0.77 CYP1A2 (0.76) HPGDCYP1A2CYP2C9HSD17B10ENPP2
SCHEMBL6778027 0.73 HPGD (0.70) HPGDCYP1A2CYP2C9HSD17B10ENPP2
SCHEMBL28456854 0.71 L3MBTL1 (0.42) MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927549-B2 Adamantyl benzamide derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2015-01-06 US disclosed
CN-102223797-A Adamantyl benzamide compounds HIGH POINT PHARMACEUTICALS LLC 2011-10-19 CN disclosed
US-20110224244-A1 Adamantyl Benzamide Derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2011-09-15 US disclosed
EP-2362730-A1 ADAMANTYL BENZAMIDE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2011-09-07 EP disclosed
WO-2010059618-A1 ADAMANTYL BENZAMIDE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224244-A1 Adamantyl Benzamide Derivatives HSD11B1, HSD17B11, HSD3B1 HPGD 25/4885CYP1A2 57/4885CYP2C9 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.